Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry (AL1TER)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by Coram Clinical Trials
Information provided by (Responsible Party):
Coram Clinical Trials Identifier:
First received: October 21, 2013
Last updated: April 21, 2017
Last verified: April 2017
This is a longitudinal, observational, non-interventional registry study, designed to collect both retrospective and prospective real world data, on patients receiving Alpha-1 augmentation therapy in the home through Coram Specialty Infusion.The data will be collected from standard Coram homecare forms, as well as patient reported case forms.

Alpha-1 Anti-trypsin Deficiency

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry

Resource links provided by NLM:

Further study details as provided by Coram Clinical Trials:

Primary Outcome Measures:
  • Change in Pulmonary Function [ Time Frame: From Baseline to 1 year ]
    Assessment of pulmonary function, including FEV1, at baseline and change (improvement or decline) at 1 year

Secondary Outcome Measures:
  • Change in Quality of Life [ Time Frame: Baseline and 6 month ]
    Patients will self complete 2 surveys, life quality index questionnaire (LQIQ) and the St. George Respiratory questionnaire that asses patients infusion experience, health improvement of infusions, pain, and cost of infusions, as well as the improvement or decline in patients perceptions of their lung and respiratory functions and activities related to that.

  • Pulmonary Infections and Exacerbation [ Time Frame: 6 months, 1 year, 2 years, 3 years. ]
    Number of pulmonary infections and exacerbation

Estimated Enrollment: 400
Study Start Date: October 2013
Estimated Study Completion Date: October 2025
Estimated Primary Completion Date: October 2020 (Final data collection date for primary outcome measure)
Adult Alpha-1 Patients
Adult Alpha-1 patients recieving augmentation therapy in the home through Coram

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients diagnosed with Alpha-1 anti-trypsin deficiency (any phenotype) on augmentation therapy

Inclusion Criteria:

  • Patients must meet the following criteria to participate in this study:

Signed informed consent Either male or female, ≥18yrs of age requiring α1-PI therapy Agree to the use of Coram's infusion services upon entry into AL1TER Registry

Exclusion Criteria:

  • Patients will be excluded from participation in the study for any of the following reasons:

Currently using an insurance provider for which Coram's services are not covered/authorized Have previously participated in the AL1TER Registry and revoked consent to the use of their Protected Health Information in theAL1TER Registry database Under the age of 18, or member of a vulnerable population (prisoner, unable to understand the English version of the consent, or unable to sign consent themselves)

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01974830

Contact: L. Allyson Checkley, PhD 303-672-8888
Contact: Loretta Kristofek, RN 321-206-3969

United States, Colorado
Coram Clinical Trials Recruiting
Denver, Colorado, United States, 80202
Contact: L. Allyson Checkley, PhD    303-672-8888   
Contact: Loretta Kristofek, RN    321-206-3969   
Principal Investigator: Donald Schmechel, MD         
Sponsors and Collaborators
Coram Clinical Trials
Principal Investigator: Donald Schmechel, MD Southeast Neurology and Memory Clinic
  More Information

Additional Information:
Responsible Party: Coram Clinical Trials Identifier: NCT01974830     History of Changes
Other Study ID Numbers: CT-10-04
Study First Received: October 21, 2013
Last Updated: April 21, 2017

Keywords provided by Coram Clinical Trials:
pulmonary function
augmentation therayp
home care

Additional relevant MeSH terms:
Alpha 1-Antitrypsin Deficiency
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Subcutaneous Emphysema
Pathologic Processes processed this record on May 25, 2017